2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2575

Validation of the RAPID-3 Questionnaire in a Cohort of Patients with Axial Spondyloarthritis
Abstract Number: 1695

Validation of Vesmeter As a Diagnostic Tool of Scleroderma
Abstract Number: 1577

Value and Prediction of Minimal Disease Activity in Patients with Psoriatic Arthritis
Abstract Number: 2987

Value of Color Doppler Ultrasound Assessment of Sacroiliac Joints in Patients with Inflammatory Chronic Low Back Pain
Abstract Number: 148

Value of Ultrasonography Parotid Glands in Patients with Suspected Primary Sjögren’s Syndrome
Abstract Number: 2122

Variation in the Prescribing Practices of Biologic Dmards
Abstract Number: 2357

Vascular Adhesion Molecule-1 Overexpression in Collagen-Induced Arthritis: Modeling Vascular Dysfunction in Rheumatoid Arthritis
Abstract Number: 840

Vascular Calcifications on Hand and Wrist Radiographs Are Associated with Cardiovascular Risk Factors, Antigen-Specific Anti-Citrullinated Protein Antibodies, and Mortality in Rheumatoid Arthritis
Abstract Number: 410

Vascular Endothelial Function Changes during Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 2567

Vascular Endothelial Growth Factor and C-Reactive Protein Serum Levels Lack Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with the Tumor Necrosis Factor-Inhibitor Golimumab
Abstract Number: 342

Vascular Permeability As an Imaging Biomarker for Chronic Inflammatory Arthritis: A Dynamic Contrast Enhanced Magnetic Resonance Imaging Study
Abstract Number: 804

Vasculitis and Inflammatory Bowel Diseases: A Study of 32 Patients with Both Conditions and Systematic Review of the Literature
Abstract Number: 1786

Vasculitis As Underlying Cause of Death in the United States: 1999 – 2010
Abstract Number: 1138

Vasoactive Intestinal Peptide (VIP) Genetic Variants Determine VIP Serum Levels and Could be Used As a Prognosis Biomarker
Abstract Number: 801

Venothromboembolism in Large Vessel Vasculitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].